Clinical Trial

Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2019 (before its estimated June 2019 completion). Its status may not reflect the trial's current state.
Summary
The combined bacteriostatic and immunomodulatory effects of erythromycin and clindamycin will be explored. Treatment effects will be extensively characterized by conventional methods including lesion counts, global assessment scales and visual grading as well as state-of-the-art methodology, including multi-modal photo analysis, perfusion by laser speckle contrast imaging, analysis of local skin surface, biopsy biomarkers and skin microbiota. This extensive response profiling, combined with the mechanistic insights from concurrent in vitro and in vivo studies in healthy volunteer challenges, will increase the understanding of erythromycin's and clindamycin's effects in acne vulgaris.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2019-03-18; most recent amendment 2025-08-06.
Status change: Recruiting → Completed 2022-03-08
Trial Details
NCT Number NCT03883269
Lead Sponsor Centre for Human Drug Research, Netherlands
Collaborators: Maruho Co., Ltd.
Conditions Acne Vulgaris
Enrollment 30 participants
Start Date 2018-03-20
Primary Completion 2019-06 (estimated)
Study Completion 2019-12 (estimated)
Updated on ClinicalTrials.gov 2019-03-20